Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial

Edward S. Kim(The University of Texas MD Anderson Cancer Center), Vera Hirsh(McGill University Health Centre), Tony Mok(Chinese University of Hong Kong), Mark A. Socinski(University of North Carolina at Chapel Hill), Radj Gervais(Centre François Baclesse), Yi‐Long Wu(Guangdong Provincial People's Hospital), Long-Yun Li(Peking Union Medical College Hospital), Claire Watkins(AstraZeneca (United Kingdom)), Mark V. Sellers(AstraZeneca (United Kingdom)), Elizabeth Lowe(AstraZeneca (United States)), Yan Sun(Peking University Cancer Hospital), Mei‐Lin Liao(Shanghai Chest Hospital), Kell Østerlind(Herlev Hospital), Martin Reck(LungenClinic Grosshansdorf), Alison Armour(AstraZeneca (United Kingdom)), Frances A. Shepherd(University of Toronto), Scott M. Lippman(The University of Texas MD Anderson Cancer Center), Jean‐Yves Douillard
The Lancet
November 1, 2008
Cited by 1,243

Abstract


Related Papers

No related papers found

Powered by citation graph analysis